For research use only. Not for therapeutic Use.
Giredestrant（Cat No.:I015425）is an orally bioavailable selective estrogen receptor degrader (SERD) developed for oncology research. It binds to estrogen receptors (ERα), inducing conformational changes that promote receptor degradation and block estrogen-driven transcriptional activity. This mechanism disrupts tumor cell growth in estrogen receptor–positive (ER+) breast cancers, including cases resistant to endocrine therapy. Giredestrant demonstrates strong potency, favorable pharmacokinetics, and reduced toxicity compared with earlier SERDs. Researchers employ it to study hormone receptor signaling, endocrine resistance mechanisms, and novel therapeutic strategies for ER+ breast cancer and related hormone-driven malignancies.
| CAS Number | 1953133-47-5 |
| Synonyms | 3-[(1R,3R)-1-[2,6-difluoro-4-[[1-(3-fluoropropyl)azetidin-3-yl]amino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluoropropan-1-ol |
| Molecular Formula | C27H31F5N4O |
| Purity | ≥95% |
| IUPAC Name | 3-[(1R,3R)-1-[2,6-difluoro-4-[[1-(3-fluoropropyl)azetidin-3-yl]amino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluoropropan-1-ol |
| InChI | InChI=1S/C27H31F5N4O/c1-16-9-20-19-5-2-3-6-23(19)34-25(20)26(36(16)14-27(31,32)15-37)24-21(29)10-17(11-22(24)30)33-18-12-35(13-18)8-4-7-28/h2-3,5-6,10-11,16,18,26,33-34,37H,4,7-9,12-15H2,1H3/t16-,26-/m1/s1 |
| InChIKey | GQCXHIKRWBIQMD-AKJBCIBTSA-N |
| SMILES | C[C@@H]1CC2=C([C@H](N1CC(CO)(F)F)C3=C(C=C(C=C3F)NC4CN(C4)CCCF)F)NC5=CC=CC=C25 |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
